Guggenheim Rates Veracyte (VCYT) buy, $65 Price Target

Guggenheim maintains its buy rating on Veracyte with a $65 price target, a 10.68% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 11:01 AM EDT · Updated Jul 1, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Veracyte, Inc. ($VCYT) "buy" with a $65 price target on June 29, 2026.

Since the rating, $VCYT is down 3.7% after 1 week, down 7.4% after 1 month and down 28.4% to date (from the $60.19 close on Jun 29, 2026).

VCYT Veracyte, Inc.

$43.12 +1.72% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim reiterated its buy rating on Veracyte, Inc. (VCYT) with a price target of $65 as of June 29, 2026.
Guggenheim's $65 price target implies 10.68% upside from Veracyte, Inc.'s ($VCYT) current $58.73 share price.
Shares of Veracyte traded near $60.49 on Monday, with a market cap of approximately $4.83 billion and a P/E ratio of 56.0.
Other analysts, including Needham and UBS, have also maintained buy ratings, while Canaccord Genuity holds a neutral stance.

Get $VCYT trade alerts by text

We text you when insiders, Congress or big funds trade $VCYT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Veracyte, Inc. alert may contain errors. Disclosures

Guggenheim has reiterated its buy rating on Veracyte, Inc. (NasdaqGM:VCYT), setting a price target of $65. This update, issued on June 29, 2026, reflects continued confidence in the company's prospects.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim maintained its buy rating on Veracyte, Inc., with a price target of $65. This aligns with recent analyst actions, as Needham also maintained a buy rating with a target of $57 on June 1, 2026. Canaccord Genuity, however, has held a more cautious stance, maintaining a hold rating with a $42 target as of May 6, 2026. UBS joined the optimistic outlook with a buy rating and a $52 target on the same date.

Veracyte, Inc. Stock Up 47.6%

Shares of Veracyte, Inc. traded near $60.49 on Monday. The company, with a market cap of approximately $4.83 billion, boasts a P/E ratio of 56.0 and a forward P/E of 31.8. Veracyte's stock has seen a 52-week low of $22.61 and a high of $60.83. The stock's 50-day moving average stands at $43.12, while the 200-day moving average is $39.05. The company maintains a robust liquidity position with a current ratio of 9.31 and a quick ratio of 8.72.

12-month forecast

$VCYT price target

Veracyte, Inc. daily closes and this analyst's $65 target. Not advice.

Recent Earnings

Veracyte reported revenue of $541.7 million, reflecting a growth rate of 21.5%. The company's net margin is 16.2%, with a return on equity of 6.9%. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at Veracyte, Inc.

Recent insider activity at Veracyte included planned sales by Karin Eastham, who sold 3,729 shares at an average price of $52.89 on June 18, 2026. On June 11, 2026, multiple insiders, including Eliav Barr and Muna Bhanji, acquired 5,272 shares each, indicating confidence in the company's future.

About Veracyte, Inc.

Veracyte, Inc. is a healthcare company specializing in diagnostics and research, headquartered in South San Francisco, California. Led by CEO Marc A. Stapley, the company employs 755 people. Veracyte develops genomic tests that improve diagnostic accuracy for diseases such as thyroid and prostate cancer.

Bottom Line

Guggenheim's reiterated buy rating on Veracyte, Inc. underscores the firm's positive outlook for the company's future. As a diagnostics leader in the healthcare sector, Veracyte continues to attract attention from analysts and investors alike. This reiteration is based on past data and may not reflect current market conditions.